The fair value estimate for Foghorn Therapeutics has been reset from US$6.00 to about US$4.17, reflecting a meaningful change in how the stock is currently modeled. This move lines up with recent Street commentary that factors in the FHD-909 setback, the end of the Eli Lilly collaboration, and a renewed focus on earlier stage programs and a leaner cost base. As you read on, you will see how analysts are updating their narrative and what to watch as the story continues to evolve.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Guggenheim, H.C. Wainwright and Stifel all keep positive ratings on Foghorn Therapeutics despite the FHD-909 setback. They point to the proprietary pipeline as offering additional shots on goal, particularly the selective EP300 degrader and other early programs.
-
Stifel highlights that Foghorn Therapeutics management plans to prioritize the wholly owned pipeline and implement organizational changes that are expected to extend the cash runway into the second half of 2029. This supports the view that the company has time to progress earlier stage assets.
🐻 Bearish Takeaways
-
Evercore ISI cut its rating to In Line and reduced its price target to US$3 from US$14. The firm points to the FHD-909 failure and the loss of Foghorn Therapeutics lead clinical opportunity, with remaining programs still at an early stage.
-
Wedbush, BTIG, TD Cowen and Citizens all moved to more cautious stances, with Wedbush cutting its target to US$2 from US$10. These firms flag the end of the Eli Lilly collaboration, limited near term catalysts and a need for additional capital or partnerships to move EP300 into the clinic.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 4 risks for Foghorn Therapeutics. See which could impact your investment.
How This Changes the Fair Value For Foghorn Therapeutics
-
Fair value estimate reduced from US$6.00 to about US$4.17.
-
Revenue growth assumption remains a decline of about 43.35% in the forecast period.
-
Assumed profit margin adjusted from roughly 17.24% to about 15.99%.
-
Future P/E multiple lowered from about 453.5x to roughly 338.6x.
-
Discount rate revised slightly from 8.18% to about 8.07%.
Never Miss an Update: Follow The Narrative
Narratives connect Foghorn Therapeutics' scientific and business story to a financial forecast and fair value that update as new information comes in. They help you see how pipeline decisions, funding and execution all feed into the investment case over time.
Head over to the Simply Wall St Community and follow the Narrative on Foghorn Therapeutics to stay up to date on:
-
How the refocus on wholly owned chromatin regulation programs such as the selective EP300, CBP and ARID1B degraders and the I&I asset shapes the business outlook.
-
The progress of key preclinical assets like the EP300 and CBP degraders, the ARID1B degrader and the timing to reach in vivo proof of concept and early human studies.
-
Risks from the loss of the FHD-909 and Eli Lilly collaboration, limited near term catalysts until around 2028 and any execution delays on decisions such as SMARCA2.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include FHTX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
